Get the Stockscreener App
6.71
1.76%
-0.12
Pre-market:
6.51
-0.20
-2.98%
Amicus Therapeutics Inc stock is traded at $6.71, with a volume of 2.75M.
It is down -1.76% in the last 24 hours and down -25.49% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$6.83
Open:
$6.78
24h Volume:
2.75M
Relative Volume:
1.03
Market Cap:
$2.06B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-19.74
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
-0.15%
1M Performance:
-25.49%
6M Performance:
-44.13%
1Y Performance:
-36.76%
1-Day Range:
$6.66
$6.915
1-Week Range:
$6.63
$6.945
52-Week Range:
$6.20
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.71 | 2.06B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 | FOLD Stock News - GuruFocus
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewswire
Jump Financial LLC Sells 105,944 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Therapeutic Market Projected To Witness - openPR.com
Granite Investment Partners LLC Purchases 166,657 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Renaissance Technologies LLC Has $19.86 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
4 Healthcare Stocks to Buy as the Sector Faces Government Heat - Yahoo Finance
(FOLD) Proactive Strategies - news.stocktradersdaily.com
Pompe Disease Treatment Market New Product Development & Latest Trends | Sanofi,Amicus Therapeutics,Genzym - openPR.com
Enzyme Replacement Therapy Market Is Booming Worldwide - openPR.com
Amicus Therapeutics (NASDAQ:FOLD) Shares Down 6.3%Should You Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week LowHere's What Happened - MarketBeat
ExodusPoint Capital Management LP Sells 537,938 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Norges Bank Invests $29.03 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In? - Insider Monkey
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Massachusetts Financial Services Co. MA Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Finance
Analysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) To Breakeven Soon - Yahoo Finance
JPMorgan Chase & Co. Cuts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock hits 52-week low at $6.99 By Investing.com - Investing.com South Africa
Vanguard Group Inc. Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock hits 52-week low at $6.99 - Investing.com
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey
49,000 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by KLP Kapitalforvaltning AS - MarketBeat
What is Zacks Research's Estimate for FOLD Q1 Earnings? - MarketBeat
Trexquant Investment LP Acquires 486,827 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. - Bluefield Daily Telegraph
AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
Old West Investment Management LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for FOLD - MarketBeat
Pictet Asset Management Holding SA Sells 110,241 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week LowHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 4,497,950 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Relative Strength Alert For Amicus Therapeutics - Nasdaq
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):